InvestorsHub on MSN
Cellectar Biosciences stock jumps after FDA grants Rare Pediatric Disease Designation
Cellectar Biosciences (NASDAQ:CLRB) shares soared 27% after the company received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its iopofosine I 131 therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback